ASM Microbe 2018: Nosopharm to present new first-inclass clinical candidate to tackle interobacteriaceae infections
NOSO-502 is on track to be the first novel antibiotic class for the Enterobacteriaceae infections to be introduced into the clinics for 40 years. First-In-Human (FIH) studies are expected to start in 2020
Lyon, France, June 8, 2018 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, announces that it has been selected to present its first-in-class clinical candidate, NOSO-502, at today’s New Agents Discovery Summary Session at ASM Microbe 2018 (June 7-11, Atlanta, GA, USA).
Full PR available here